Gland Pharma Limited has submitted a regulatory filing to the BSE Limited and the National Stock Exchange of India Limited. The purpose of the filing is to intimate the exchanges about a scheduled meeting with an institutional investor, as required by securities regulations.
The disclosure is made specifically pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Meeting Details
A one-on-one meeting has been scheduled with Kotak Mutual Fund. The meeting is set to take place on September 09, 2026.
The company has included a disclaimer stating that the schedule is subject to change. Any change may occur due to exigencies on the part of the investor, analyst, or the company itself.
The letter was signed by Pallerlamudi Sampath Kumar, who holds the position of Company Secretary & Compliance Officer at Gland Pharma Limited.